Related Experiment Videos
Cost effectiveness of carvedilol for heart failure
T E Delea1, M Vera-Llonch, R E Richner
1Policy Analysis Inc., Brookline, Massachusetts 02445, USA.
Insights
Carvedilol improves life expectancy for chronic heart failure (CHF) patients. This heart failure drug offers cost-effective treatment, providing significant value even with conservative benefit assumptions.
Area of Science:
- Pharmacoeconomics
- Cardiology
- Health Services Research
Background:
- Chronic heart failure (CHF) presents a significant burden on healthcare systems.
- Evaluating the cost-effectiveness of pharmacological interventions is crucial for optimal resource allocation.
Purpose of the Study:
- To assess the cost-effectiveness of carvedilol in treating patients with chronic heart failure (CHF).
- To compare the projected life expectancy and lifetime medical costs of CHF patients receiving carvedilol plus conventional therapy versus conventional therapy alone.
Main Methods:
- A Markov model was utilized to simulate outcomes for a hypothetical cohort of CHF patients.
- The model projected life expectancy and lifetime medical care costs under two scenarios: limited and extended benefits of carvedilol.
- Data from the US Carvedilol Heart Failure Trials Program and other sources were used for model estimation.
Main Results:
- Carvedilol use was associated with increased life expectancy (6.98-7.62 years) compared to conventional therapy alone (6.67 years).
- Lifetime costs for carvedilol treatment were higher ($36,420-$38,867) than conventional therapy ($28,756).
- The cost per life-year saved ranged from $12,799 to $29,477, demonstrating favorable cost-effectiveness.
Conclusions:
- Carvedilol is a cost-effective treatment option for chronic heart failure (CHF).
- Its cost-effectiveness compares favorably with other accepted medical interventions, even under conservative benefit duration assumptions.
Abstract:
In this study, we examine the cost effectiveness of carvedilol for the treatment of chronic heart failure (CHF). We use a Markov model to project life expectancy and lifetime medical care costs for a hypothetical cohort of patients with CHF who were assumed alternatively to receive carvedilol plus conventional therapy (digoxin, diuretics, and angiotensin-converting enzyme inhibitors) or conventional therapy alone. Patients on carvedilol were assumed to experience a reduced risk of death and hospitalization for CHF, which is consistent with findings from the US Carvedilol Heart Failure Trials Program. The benefits of carvedilol were projected under 2 alternative scenarios. In the first ("limited benefits"), benefits were conservatively assumed to persist for 6 months, the average duration of follow-up in these clinical trials, and then end abruptly. In the other ("extended benefits"), they were arbitrarily assumed to persist for 6 months and then decline gradually over time, vanishing by the end of 3 years. We estimated our model using data from the US Carvedilol Heart Failure Trials Program and other sources. For patients receiving conventional therapy alone, estimated life expectancy was 6.67 years; corresponding figures for those also receiving carvedilol were 6.98 and 7.62 years under the limited and extended benefits scenarios, respectively. Expected lifetime costs of CHF-related care were estimated to be $28,756 for conventional therapy, and $36,420 and $38,867 for carvedilol (limited and extended benefits, respectively). Cost per life-year saved for carvedilol was $29,477 and $12,799 under limited and extended benefits assumptions, respectively. The cost effectiveness of carvedilol for CHF compares favorably to that of other generally accepted medical interventions, even under conservative assumptions regarding the duration of therapeutic benefit.